Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Quantum Biopharma ( (TSE:QNTM) ) is now available.
On June 17, 2025, Quantum BioPharma announced the first scanning of a multiple sclerosis (MS) patient in a joint study with Massachusetts General Hospital. This study aims to validate a novel PET imaging technique for monitoring myelin integrity, which could enhance the efficacy testing of Quantum’s investigational MS drug, Lucid-21-302. The new PET-MR scanner used in the study improves the accuracy and patient experience, potentially advancing treatment monitoring for MS. This development could strengthen Quantum BioPharma’s position in the biopharmaceutical industry, particularly in the MS treatment market, by providing a more precise method to measure drug efficacy.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is advancing its lead compound, Lucid-MS, which has shown potential in preclinical models to prevent and reverse myelin degradation, a key factor in multiple sclerosis. Quantum BioPharma also has a strategic investment portfolio and retains a stake in Unbuzzd Wellness Inc., which markets an OTC product for alcohol misuse.
Average Trading Volume: 8,446
Technical Sentiment Signal: Hold
Current Market Cap: C$82.87M
See more data about QNTM stock on TipRanks’ Stock Analysis page.